Six Years After COVID's Global Alarm, Pandemic Readiness Remains a Half-Built House

On January 30, 2019, the World Health Organization declared COVID-19 a Public Health Emergency of International Concern. Six years on, the question of whether the world is meaningfully better prepared for the next pandemic is one that scientists, health economists, and policymakers keep circling back to, and the honest answer is: partially, and unevenly.

The pandemic exposed fault lines that had been visible to epidemiologists for decades. Fragile supply chains for personal protective equipment, vaccine manufacturing concentrated in a handful of wealthy nations, and surveillance systems that were either underfunded or politically constrained all contributed to a response that was slower and more chaotic than it needed to be. The death toll, conservatively estimated at nearly 7 million by the WHO and likely far higher when excess mortality is factored in, made the cost of that unpreparedness impossible to ignore.

The most tangible legacy of COVID-19 is the acceleration of mRNA vaccine technology. What had been a promising but largely theoretical platform was stress-tested at global scale, and it worked. The Pfizer-BioNTech and Moderna vaccines were developed, trialed, and authorized within roughly a year, a timeline that would have seemed fantastical before 2020. That technological leap is real, and it has reshaped how pharmaceutical companies and governments think about rapid-response vaccine development. The Coalition for Epidemic Preparedness Innovations, known as CEPI, has since committed to a goal of compressing vaccine development to 100 days for any new pathogen of pandemic potential.

Surveillance infrastructure has also improved in pockets. Genomic sequencing capacity expanded dramatically during COVID, and many countries that previously had little to no sequencing capability now have functioning programs. The WHO's Hub for Pandemic and Epidemic Intelligence, launched in Berlin in 2021, represents an institutional attempt to consolidate and analyze outbreak data more proactively. These are genuine advances.

But the structural inequities that defined COVID's global response have not been resolved. The COVAX facility, designed to ensure equitable vaccine access, ultimately delivered far fewer doses to low-income countries than promised, and far later than needed. The intellectual property debates that stalled generic vaccine production in the Global South were never fully settled. A proposed pandemic treaty, years in negotiation under WHO auspices, has repeatedly stalled over disagreements between wealthy and developing nations on pathogen sharing, technology transfer, and financing. As of early 2025, a binding global agreement remains elusive.

There is a systems-level dynamic at work here that rarely gets the attention it deserves. Pandemic preparedness is a classic example of what researchers call an "invisible dividend" problem. When prevention works, nothing happens, and nothing happening generates no political reward. Governments that invest heavily in stockpiles, surveillance, and international coordination see no visible return during quiet years, while governments that cut those budgets face no immediate consequence. This creates a structural incentive to underinvest, and COVID did not fundamentally change that calculus.

In the United States, the Biden administration's pandemic preparedness budget requests were repeatedly trimmed by Congress. The Trump administration's return to power in 2025 brought renewed skepticism of multilateral health institutions, including signals of reduced engagement with the WHO. Globally, the political will that briefly coalesced around pandemic reform in 2021 and 2022 has dissipated as COVID receded from daily life.

The second-order consequence worth watching is what this political erosion does to the scientific workforce. Epidemiologists, public health officials, and global health researchers who surged into pandemic-related roles over the past five years are now facing funding cuts, institutional uncertainty, and in some cases active hostility from governments skeptical of expert-led health policy. If that talent disperses, rebuilding it when the next outbreak arrives will take years the world may not have.

The 100-day vaccine ambition is real and worth celebrating. The genomic tools are sharper. But a faster vaccine means little if the distribution architecture is still broken, if the treaty framework is still unsigned, and if the agencies responsible for early warning are being defunded in real time. The next pandemic will not wait for the politics to catch up.